ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Cohort Study"

  • Abstract Number: L06 • ACR Convergence 2021

    Comparative Safety of Gout “Treat-to-target” and “Usual Care” Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach

    Kazuki Yoshida, Jun Liu, Daniel Solomon, Robert J Glynn and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Rheumatology societies recommend serum-urate (SU)-driven treat-to-target (TTT) strategies for the management of gout. However, cardiovascular (CV) safety of urate-lowering therapy (ULT) has been questioned.…
  • Abstract Number: 0258 • ACR Convergence 2021

    Developing Electronic Health Record Algorithms That Accurately Identify Patients with Juvenile Idiopathic Arthritis

    Hannah Peterson1, April Barnado2 and Anna Patrick2, 1Lipscomb University College of Pharmacy, Nashville, TN, 2Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Electronic Health Records (EHRs) store nearly all clinical data in one central location providing increased accessibility, accuracy, and security. At our institution, the Synthetic…
  • Abstract Number: 0816 • ACR Convergence 2021

    Analysis of Abatacept Treatment Retention and Efficacy According to Disease Duration and Treatment Line in a Real-World Setting

    Rieke Alten1, Xavier Mariette2, Rene-Marc Flipo3, Roberto Caporali4, Maya Buch5, Yusuf Patel6, Raimon Sanmarti7, Sara Marsal8, Michael Nurmohamed9, Hedley Griffiths10, Peter Peichl11, Bettina Bannert12, Adrian Forster13, Melanie Chartier14, Yedid Elbez15, Christiane Rauch16, Vadim Khaychuk17 and Karissa Lozenski17, 1Schlosspark-Klinik University, Berlin, Germany, 2Université Paris-Saclay, AP-HP, Hospital Bicêtre, Paris, France, 3Centre Hospitalier Universitaire de France, Lille, France, 4Policlinico S. Matteo University, Pavia, Italy, 5University of Leeds, Leeds, United Kingdom, 6Hull Royal Infirmary, Hull, United Kingdom, 7Hospital Clínic de Barcelona, Barcelona, Spain, 8Hospital Universitari Vall d’Hebron, Barcelona, Spain, 9ARC Amsterdam University Hospitals – VU University Medical & Reade, Amsterdam, Netherlands, 10Barwon Rheumatology Service, Geelong, Australia, 11Evangelical Hospital, Vienna, Austria, 12Universitätsspital Basel, Basel, Switzerland, 13Schulthess Klinik, Zürich, Switzerland, 14Bristol Myers Squibb, Rueil-Malmaison, France, 15Deepscover, Puteaux, France, 16Bristol Myers Squibb, Munich, Germany, 17Bristol Myers Squibb, Princeton, NJ

    Background/Purpose: Longer disease duration and greater number of prior DMARDs have been associated with lower treatment efficacy in patients with RA.1 Abatacept is a biologic…
  • Abstract Number: 1427 • ACR Convergence 2021

    Reduction of Cardiovascular Disease and Mortality versus Risk of New Onset Diabetes with Statin Use in Patients with Rheumatoid Arthritis

    Gulsen Ozen1, Sophie Dell’Aniello2, Sofia Pedro3, Kaleb Michaud4 and Samy Suissa5, 1University of Nebraska Medical Center, Bellevue, NE, 2Center for Clinical Epidemiology, Lady Davis Research Institute - Jewish General Hospital, Montréal, QC, Canada, 3Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 4University of Nebraska Medical Center, Omaha, NE, 5Center for Clinical Epidemiology, Lady Davis Research Institute - Jewish General Hospital;Depts of Epidemiology and Biostatistics and of Medicine, McGill University, Montréal, QC, Canada

    Background/Purpose: The risks of death and of type 2 diabetes mellitus (T2DM) are increased in RA mainly due to inflammation mediated accelerated cardiovascular disease (CVD)…
  • Abstract Number: 1879 • ACR Convergence 2021

    Delayed Diagnosis of IgG4 Related Disease Is Associated with Worse Outcome: A Retrospective, Real-life Observational Study

    Elisheva Pokroy-Shapira1, Iftach Sagy2, Katya Meridor3 and Yair Molad4, 1Institute of Rheumatology, Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petach Tikva, Israel, 2Clinical Research Center, Soroka University Medical Center, Beer Sheva and Ben Gurion University of the Negev, DVIRA, Israel, 3Tel Aviv Sourasky Medical Center, Kfar Saba, Israel, 4Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel

    Background/Purpose: The purpose of this study was to characterize clinical and pathological features as well as disease outcome of an Israeli incident cohort of patients…
  • Abstract Number: 0368 • ACR Convergence 2021

    Geographical Prevalence of Family History in Patients with Axial SpA and Its Association with HLA-B27: Data from the Worldwide ASAS-perSpA Study

    Miranda van Lunteren1, Anne Boel1, Clementina López Medina2, Joachim Sieper3, Désirée van der Heijde4 and Floris van Gaalen1, 1Leiden University Medical Center, Leiden, Netherlands, 2Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, 3Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 4Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands

    Background/Purpose: Research has shown that in patients with axial spondyloarthritis (axSpA), the most common form of spondyloarthritis (SpA) in a family history is axSpA. Moreover,…
  • Abstract Number: 0818 • ACR Convergence 2021

    Biologics Initiation in Moderate vs Severe Rheumatoid Arthritis Patients: Prospective Observational Study from a Canadian Registry

    Nancy Guo1, Xiuying Li2, Mohammad Movahedi3, Angela Cesta4 and Claire Bombardier5, 1Kingston General Hospital, Kingston, ON, Canada, 2OBRI at University Health Network, Toronto, ON, Canada, 3Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 4Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, 5University of Toronto - Toronto, Toronto, ON, Canada

    Background/Purpose: Prior studies have shown that in the real-world setting, rheumatoid arthritis (RA) patients have lower disease activity than those studied in clinical trials. However,…
  • Abstract Number: 1493 • ACR Convergence 2021

    Association of the Soluble Terminal Complement Complex C5b-9 (sC5b-9) with Urinary Signs of Kidney Disease in a Swiss SLE Cohort

    Kristin Schmiedeberg1, Ruediger B. Mueller2, Thomas Neumann3, Ian Pirker1, Philipp Rein4, Camillo Ribi5, Andrea Rubbert-Roth6, Michael Kirschfink7, Jutta Schroeder-Braunstein7, Reinhard Voll8 and Johannes von Kempis1, 1Kantonsspital St. Gallen, St.Gallen, Switzerland, 2Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Switzerland, 3Kantonsspital St.Gallen, St.Gallen, Switzerland, 4Landeskrankenhaus Hohenems, Wolfurt, Austria, 5CHUV, Lausanne, Switzerland, 6Kantonspital St Gallen, St.Gallen, Switzerland, 7Universitätsklinikum Heidelberg, Heidelberg, Germany, 8Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany

    Background/Purpose: Few reliable laboratory biomarkers exist to determine disease activity in SLE. The role of the soluble terminal complement complex, sC5b-9, in active SLE has…
  • Abstract Number: 0388 • ACR Convergence 2021

    Prediction Tool for Damage Accrual Trajectory in Incident Systemic Sclerosis

    Ariane Barbacki1, Ada Man2, Mianbo Wang3, Dylan Johnson4, Yuqing Zhang5, Mandana Nikpour6 and Murray Baron7, 1McGill University, Montral, Montréal, QC, Canada, 2University of Manitoba, Winnipeg, MB, Canada, 3Lady Davis institute for Medical Research, Montréal, QC, Canada, 4University of Alberta, Edmonton, AB, Canada, 5Massachusetts General Hospital, Quincy, MA, 6University of Melbourne at St Vincent's Hospital, Melbourne, Australia, 7Jewish General Hospital, Montréal, QC, Canada

    Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease associated with the accrual of organ damage over time, which can be measured using the Scleroderma…
  • Abstract Number: 0826 • ACR Convergence 2021

    Diagnosis, Treatment and Utilization Changes in Rheumatoid Arthritis Patients Before and During COVID-19

    Miao Wang1, Sylvie Lardeux2, Elisea Avalos-Reyes3, Michele Hamburger4 and Kjel Johnson5, 1CVS Health, New York, NY, 2CVS Health, Wellesley, MA, 3CVS Health, Irving, TX, 4Frances Hamburger Institute, Hauppauge, NY, 5CVS Health, Lincoln, RI

    Background/Purpose: During the COVID-19 pandemic, individuals were encouraged to shelter in place, specifically those considered high risk for COVID-19. Rheumatoid arthritis (RA) patients are known…
  • Abstract Number: 1522 • ACR Convergence 2021

    Potential Predictors of Persistence in Immune Check Point Inhibitor Induced Arthritis

    Anu Desai1, Lakshmi Priya Shadananan1, Adam Croft2, Lalit Pallan1, Neil Steven3 and Benjamin Fisher4, 1University of Birmingham, Birmingham, United Kingdom, 2University of Birmingham, Halesowen, United Kingdom, 3Institute of Immunology and Immunotherapy/University of Birmingham, Birmingham, United Kingdom, 4Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

    Background/Purpose: Immune Check Point Inhibitors (ICIs) are widely used in Oncology and are associated with multiple autoimmune and systemic inflammatory reactions called immune-related adverse events.…
  • Abstract Number: 0417 • ACR Convergence 2021

    Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study

    Rula Hajj-Ali1, Robert Butler2, Carol Langford3, Leonard Calabrese2, David Cuthbertson4, Nader Khalidi5, CURRY LEE MD KOENING6, Carol McAlear7, Paul Monach8, Larry Moreland9, Christian Pagnoux10, Philip Seo11, Ulrich Specks12, Antoine Sreih7, Kenneth Warrington13 and Peter Merkel7, 1Cleveland Clinic, Hunting Valley, OH, 2Cleveland Clinic, Cleveland, OH, 3Cleveland Clinic, Moreland Hills, OH, 4University of South Florida, Tampa, FL, 5McMaster University, Hamilton, ON, Canada, 6LIMITED TO OFFICIAL UNIVERSITY DUTIES ONLY, Salt Lake City, UT, 7University of Pennsylvania, Philadelphia, PA, 8Brigham and Women's Hospital, Boston, MA, 9University of Colorado, Denver, CO, 10Mount Sinai Hospital, Toronto, ON, Canada, 11Johns Hopkins University, Baltimore, MD, 12Mayo Clinic, Rochester, MN, 13Mayo Clinic, Rochester, Minnesota

    Background/Purpose: The prevalence of neurologic involvement (NI) in ANCA-associated vasculitis (AAV), especially central nervous system (CNS) involvement, is not well characterized. This project aimed to…
  • Abstract Number: 0827 • ACR Convergence 2021

    Discontinuation Rate of Tofacitinib as Monotherapy Is Similar Compared to Combination Therapy with Methotrexate in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada

    Mohammad Movahedi1, Denis Choquette2, Louis Coupal2, Angela Cesta3, Xiuying Li3, Edward Keystone4 and Claire Bombardier5, 1Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 2Institut de Rhumatologie de Montréal, Montréal, QC, Canada, 3Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, 4Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 5University of Toronto - Toronto, Toronto, ON, Canada

    Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment and is prescribed alone or with methotrexate (MTX). We previously…
  • Abstract Number: 1539 • ACR Convergence 2021

    High Disease Activity, as Assessed by RAPID3, Increases Risk of Hospitalization and Predicts Lower Chance of Recovery from COVID-19 in a Cohort of Tertiary Care Rheumatology Patients

    Matas Orentas1, Sonali Khandelwal2, Michael Grant2, Yanyu Zhang1, Najia Shakoor2 and Sobia Hassan1, 1RUMC, Chicago, IL, 2Rush University, Chicago, IL

    Background/Purpose: There is a need to understand which patients with rheumatologic diseases may be at highest risk for poor COVID-19 related outcomes so that both…
  • Abstract Number: 0450 • ACR Convergence 2021

    Identifying Trajectories of Radiographic Spinal Disease in Ankylosing Spondylitis

    Mark Hwang1, Minjae Lee2, Lianne Gensler3, Matthew Brown4, Amirali Tahanan5, Mohammad Rahbar6, Theresa Hunter7, Mingyan Shan8, Mariko Ishimori9, John Reveille10, Michael Weisman11 and Thomas Learch12, 1McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, 2UT Southwestern, Dallas, TX, 3Department of Rheumatology, University of California San Francisco, San Francisco, CA, 4King's College London, London, United Kingdom, 5McGovern Medical School, Houston, TX, 6Division of Clinical and Translational Sciences, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, 7Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, IN, 8Eli Lilly and Company, Indianapolis, IN, 9Cedars-Sinai Health System, Los Angeles, CA, 10Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, 11Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, 12Cedars-Sinai, Los Angeles, CA

    Background/Purpose: Little is known about the natural history of spinal disease in Ankylosing Spondylitis (AS). Our objective was to identify distinct patterns of change in…
  • 1
  • 2
  • 3
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies